Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15044629 | 1.00 | ACACB (0.38) | ACACBALOX5NR1D1SMN1; SMN2LMNA | |
| SCHEMBL21852438 | 0.96 | MAOB (0.38) | ACACBALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL8668171 | 0.95 | ACACB (0.37) | ACACBALOX5NR1D1 | |
| SCHEMBL8335482 | 0.94 | ACACB (0.40) | ACACBALOX5NR1D1SMN1; SMN2LMNA | |
| SCHEMBL15044628 | 0.93 | ACACB (0.34) | ACACBALOX5NR1D1SMN1; SMN2LMNA | |
| SCHEMBL22304893 | 0.92 | LTA4H (0.37) | ACACBALOX5ALDH1A1 | |
| SCHEMBL7516386 | 0.91 | PTPN1 (0.41) | ACACBNR1D1RAB9A | |
| SCHEMBL8099592 | 0.89 | SMN1; SMN2 (0.40) | NR1D1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21852439 | 0.88 | MAOB (0.35) | ACACBALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL8099090 | 0.88 | SMN1; SMN2 (0.44) | ALOX5NR1D1SMN1; SMN2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158241-A1 | Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist® | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | claimed |
| EP-2580184-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | Bayer Intellectual Property GmbH (DE) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154333-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | claimed |
| EP-3464237-B1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2023-12-20 | — | — | EP | disclosed |
| CN-110101875-B | Gadoxetic acid disodium injection pharmaceutical composition and preparation method thereof | 四川科伦药物研究院有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-10-19 | — | — | US | disclosed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | disclosed |
| EP-3464237-A1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-04-10 | — | — | EP | disclosed |
| US-20130158241-A1 | Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist® | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158241-A1 | Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist® | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| CN-103068790-A | Process for preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid and use for production of primovist tm | BAYER IP GMBH | 2013-04-24 | — | — | CN | disclosed |
| EP-2580184-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | Bayer Intellectual Property GmbH (DE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2580184-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | Bayer Intellectual Property GmbH (DE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154333-A3 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011154333-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154333-A2 | PROCESS FOR PREPARING CRYSTALLINE 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)-4-(4-ETHOXYBENZYL)UNDECANEDIOIC ACID AND USE FOR PRODUCTION OF PRIMOVIST® | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158241-A1 | Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist® | POF1B, STT3B, CA9 | ACACB 1577/4885ALOX5 1131/4885NR1D1 3891/4885 |
| US-11149041-B2 | Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium) | CA9, CA4, GLRX3 | ACACB 3057/4885ALOX5 3249/4885NR1D1 2632/4885 |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | GLRX3, CA9, CA4 | ACACB 3088/4885ALOX5 2520/4885NR1D1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.